Список проголосовавших за комментарий " Global Blood Therapeutics assumed with a Outperform at Wedbush; tgt $73 (37.35)Wedbush assumes coverage of GBT with a Outperform and sets target price at $73. Firm notes GBT is developing GBT440 to reduce the severity and frequency of crises and pain associated with sickle cell disease (SCD) and to improve blood oxygenation characteristics and quality of life for IPF. <strong>In 2017, they see release of Phase 2a GBT440 testing in IPF as the most material catalyst unless GBT is acquired.</strong> Firm also calculates that the recent uptick following acquisition speculation is too low."